Catalog No.
DHJ28415
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG
Clonality
Monoclonal
Target
T-cell immunoglobulin mucin receptor 3, HAVcr-2, TIMD-3, T-cell membrane protein 3, HAVCR2, Hepatitis A virus cellular receptor 2, CD366, TIMD3, TIM-3, TIM3, T-cell immunoglobulin and mucin domain-containing protein 3, B7-H1, Programmed cell death 1 ligand 1, PDCD1 ligand 1, PDCD1L1, B7 homolog 1, PDCD1LG1, PDL1, hPD-L1, Programmed death ligand 1, B7H1, PD-L1, CD274
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q8TDQ0 & Q9NZQ7
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
Bispecific
Clone ID
LY3415244
T lymphocyte heterogeneity in NSCLC: implications for biomarker development and therapeutic innovation., PMID:40510347
Integrative Analysis of EPHX4 as a Novel Prognostic and Diagnostic Biomarker in Lung Adenocarcinoma., PMID:40507905
Enhanced anti-tumor activity by zinc finger repressor-driven epigenetic silencing of immune checkpoints and TGFBR2 in CAR-T cells and TILs., PMID:40487483
Genetically engineered T cell membrane-camouflaged nanoparticles triggered cuproptosis for synergistic bladder cancer photothermal-immunotherapy., PMID:40481464
Persistence of hepatitis C virus in peripheral blood mononuclear cells of patients who achieved sustained virological response following treatment with direct-acting antivirals is associated with a distinct pre-existing immune exhaustion status., PMID:40481150
Cognate Nanovaccine Promotes Tertiary Lymphoid Structures Function and Strengthens Immune Cell Cross-Talk by Targeting Exhausted T Cells in Nonimmunogenic Cancers., PMID:40478679
TIM3 and TIGIT-expressing CD4 T cells are impacted by kidney transplantation and associated with risk of infection., PMID:40475763
CD70 CAR-T cells empowered by TS-2021 through ex vivo transduction show potent antitumor efficacy against glioblastoma., PMID:40474210
Immune checkpoint molecules and spatial transcriptome profiles according to BRAF status in acral melanoma., PMID:40459254
TP53-Mutated Acute Myeloid Leukemia: Unanswered Questions., PMID:40459096
TIM3-blockade synergizes with IL2 in alleviating intra-tumoral CD8+T cell exhaustion., PMID:40456747
RUNX1/SLAMF3 Axis Drives Immunosuppression to Contribute to Colorectal Cancer Liver Metastasis by Blocking Phagocytosis and Depleting C1QC+ Tumor-Associated Macrophages., PMID:40448626
Role of galectin-9 in the development of gestational diabetes mellitus., PMID:40447728
Galectin-9 induces IL-1β production as a key inflammatory cytokine in the acute myeloid leukemia cell line (U937)., PMID:40444162
It's high TIM-3 for armored CAR-T therapy for B-ALL., PMID:40440046
CD49a+ NK cells promote esophageal cancer development by inducing MDCSs infiltration via GM-CSF., PMID:40437020
The expression patterns and prognostic significance of PD-1 and TIM-3 on T cells and the differentiated subsets in acute myeloid leukemia., PMID:40423811
Comprehensive analysis of immune checkpoint molecules profiles phenotype and function of exhausted T cells in enzootic bovine leukosis., PMID:40420409
Unravelling T cell exhaustion through co-inhibitory receptors and its transformative role in cancer immunotherapy., PMID:40415479
Expression of TIM-3 in transitional cell carcinoma: A comparative study of tissue and serum levels., PMID:40414078
Breaking the immune desert: Strategies for overcoming the immunological challenges of pancreatic cancer., PMID:40412630
KK2845, a PBD dimer-containing antibody-drug conjugate targeting TIM-3-expressing AML., PMID:40404985
Mechanism of LINC01018/miR-182-5p/Rab27B in the immune escape through PD-L1-mediated CD8+ T cell suppression in glioma., PMID:40399992
Immune checkpoint inhibitor (ICI) therapy in central nervous system cancers: State-of-the-art and future outlook., PMID:40394797
Unraveling the immunomodulatory role of TIM-3 in head and neck squamous cell carcinoma: implications for targeted therapy., PMID:40392355
Alterations in CD8+CD45RA+CCR7- T cells as a potential biomarker for primary Sjögren's syndrome., PMID:40388849
CD73+CD8+ T cells define a subset with anti-tumor potential in DLBCL patients., PMID:40385579
Comparative efficacy of febuxostat and vitamin E in the management of MASLD: Insights from a randomized parallel clinical study., PMID:40383220
Immune checkpoint inhibitors and immunosuppressive tumor microenvironment: current challenges and strategies to overcome resistance., PMID:40376861
Increased expression of the PD-1/PD-L1 regulatory axis in tissue leukocytes from experimental actinomycetoma by Nocardia brasiliensis in BALB/c mice., PMID:40368069
The significant impact of T-cell immunoglobulin and mucin domain 3(Tim-3) gene polymorphism on HCV infection and viral load., PMID:40367470
Single-cell analysis reveals potential therapeutic markers of peripheral blood mononuclear cells from bladder cancer patients., PMID:40367012
Enhancing mesothelin CAR T cell therapy for pancreatic cancer with an oncolytic herpes virus boosting CAR target antigen expression., PMID:40366419
Knockdown of TIM3 Hampers Dendritic Cell Maturation and Induces Immune Suppression by Modulating T-Cell Responses., PMID:40362568
New Therapeutic Targets TIGIT, LAG-3 and TIM-3 in the Treatment of Advanced, Non-Small-Cell Lung Cancer., PMID:40362333
Revealing the mechanisms and therapeutic potential of immune checkpoint proteins across diverse protein families., PMID:40356928
Dupilumab-induced inhibition of myeloid dendritic cell function via TIM-3-TGF-β1 feedback loop in treatment of atopic dermatitis., PMID:40347980
Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception., PMID:40345189
Immune evolution in pre-invasive lung adenocarcinoma., PMID:40345186
TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives., PMID:40332725
The role of Tim-3+T cell subsets in the peripheral blood of patients with COVID-19 and diabetes., PMID:40330891
Targeting exon mutations in NSCLC: clinical insights into LAG-3, TIM-3 pathways, and advances in fourth-generation EGFR-TKIs., PMID:40325239
TIM-3 regulates microglial function., PMID:40316829
Plasma levels of soluble PD-1, TIM-3, LAG-3 and galectin-3 and the degree of liver fibrosis in CHC and the impact of successful antiviral treatment on their levels., PMID:40316644
DNMT1 promotes bladder cancer progression and immune escape by inhibiting MYH11 expression by methylating its promoter., PMID:40314887
Immune checkpoint for pregnancy., PMID:40314833
Immune biomarkers in circulating cells of NSCLC patients can effectively evaluate the efficacy of chemotherapy combined with anti-PD-1 therapy., PMID:40308600
Identification of soluble biomarkers that associate with distinct manifestations of long COVID., PMID:40307449
Somatic TP53 Mutations Drive T and NK Cell Dysfunction in AML and Can be Rescued by Reactivating Wild Type p53., PMID:40297420
Single-nucleus RNA sequencing reveals a preclinical model for the most common subtype of glioblastoma., PMID:40295632
For research use only. Not for human or drug use.
